Ticker HubNasdaq

TSHA

Taysha Gene Therapies, Inc. Common Stock

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Latest afterhours mover

Latest price

$4.21-0.24%

As of Oct 30, 2026, 6:55 PM EDT · Market data by Massive

Market cap

$1.4B

Volume

1.5M

Previous close

$4.22

Day range

$4.07 – $4.25

Listed

Sep 24, 2020

Coverage

0 articles

Price performance

Recent trading

5 trading days · 15-minute intervals · ET

Five-day open $3.98Latest interval $4.21

Newsroom

Latest TSHA coverage

No matching articles yet.

Recent catalyst headlines

Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?

Oct 19, 2026

Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value

Oct 9, 2026

Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?

Oct 9, 2026

Company overview

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 99
Headquarters: DALLAS, TX
CIK: 0001806310

Company website View advanced chart

SEC filings

No filing records are attached to this profile yet.

Browse EDGAR

Profile at a glance

Sep 24, 2020

Listed

Employees

Market data may be delayed and is provided for informational purposes only. SmallCapsDaily content is not investment advice.